REFERENCES
- M. J. Derelanko, and M. A. Hollinger. CRC Handbook of Toxicology. CRC Press, USA, (2001) .
- DOH, and Guidelines for the Nonclinical Pharmacology/Toxicology Studies for Medicinal Products Applications,3rd. ROC, Taiwan, (2000) .
- FDA, and Single Dose Acute Toxicity Testing for Pharmaceuticals. USA, , (1996) .
- JMHW, and Guidelines for Toxicity Studies of Drugs. Japan, , (1993) .
- H. F. Kung, Z. Guo, J. Billings, X. Xu, R. H. Mach, M. Blau, and R. E. Ackerhalt. (1988). Preparation and biodistribution of [123I]IBZM: A potential CNS D-2 dopamine receptor imaging agent. Nucl. Med. Biol. 15:195–201.
- M. Bobeldijk, N. P. L. G. Verhoeff, J. A. J. M. Vekemans, H. M. Buck, P. A. P. M. van Doremalan, J. J. van Hoof, and A. G. M. Janssen. (1990). A simple and high-yield synthesis of (S)-BZM, (R)-BZM and (S)-IBZM for the preparation of (S)123I-IBZM. J. Lab. Comp. Radiopharm. 28:1247–1256.
- M. B. Ronald, Fu Xing, Nora S. Kula, J. B. Ross, A. Louis, B. I. Robert, and D. T. Gilles. (2003). Synthesis and Affinity of a Possible Byproduct of Electrophilic Radiolabeling of [123I]IBZM. Bio. Med. Chem. Let. 13:4015–4017.
- P. J. Kostyniak, J. S. Brenner, A. E. Maccubbin, S. Nakeeb, R. Kasliwal, and H. F. Kung. (1988). The toxicity and mutagenicity of S-3-iodo-N-(1-ethyl-2-pyrrolidinyl) methyl-2-hydroxy-6-methoxybenzamide (IBZM), a new CNS D-2 dopamine receptor imaging agent. Drug Chem. Toxicol. 11 (4):433–42.